Skip to main content
Celon Pharma S.A. logo

Celon Pharma S.A. — Investor Relations & Filings

Ticker · CLN ISIN · PLCLNPH00015 LEI · 259400Q0ERJT0NC5DT24 WAR Manufacturing
Open in API
Filings indexed 709 across all filing types
Latest filing 2021-02-16 Management Reports
Country PL Poland
Listing WAR CLN

About Celon Pharma S.A.

https://celonpharma.com/en/

Celon Pharma S.A. is an integrated pharmaceutical company that conducts advanced research and manufactures modern drugs. The company is engaged in the development, production, distribution, and marketing of therapeutic solutions. Its primary focus is on developing treatments for cancers, neurological diseases, diabetes, and other metabolic disorders. As a marketing authorization holder, Celon Pharma manages the full product lifecycle, from scientific research and development to commercialization, aiming to improve patient health and quality of life.

Recent filings

Filing Released Lang Actions
Załącznik do Uchwały nr 4 NWZ Celon Pharma S.A.
Management Reports Classification · 1% confidence The document is titled "OPINIA ZARZĄDU CELON PHARMA S.A." (Management Opinion of Celon Pharma S.A.) and is explicitly stated as an attachment to a resolution from an Extraordinary General Meeting (Nadzwyczajne Walne Zgromadzenie). The content is a detailed opinion from the Management Board regarding the authorization to raise capital through a targeted share issue, including the potential exclusion of pre-emptive rights (prawo poboru). This document provides management's rationale and justification for a significant corporate action (capital increase/financing) that will be voted upon by shareholders. This aligns best with the function of providing detailed management commentary and justification, which is characteristic of Management Reports (MDA) or, given the context of a shareholder meeting resolution, potentially related to proxy materials. However, since it is a formal 'Opinion of the Management Board' detailing financial needs, strategy for capital raising, and justification for proposed shareholder resolutions, it fits the description of a Management Report (MDA) which covers management's explanation of business trends and outlook related to financial decisions. It is not a full Annual Report (10-K), an Earnings Release (ER), or a simple announcement of a report (RPA). The context of the Extraordinary General Meeting (EGM) suggests it is a key document presented to shareholders for decision-making, often accompanying proxy materials, but the core content is the management's detailed justification for the proposed capital structure change.
2021-02-16 Polish
Uchwały NWZ Celon Pharma S.A.
AGM Information Classification · 1% confidence The document text consists of multiple resolutions ('Uchwała nr X/2021') passed by an 'Nadzwyczajne Walne Zgromadzenie' (Extraordinary General Meeting) of Celon Pharma S.A. on February 16, 2021. These resolutions cover procedural matters (electing a chairman), approving the agenda, and making significant corporate decisions like authorizing capital increases, amending the company's charter (Statut), and changing the scope of business activities. The core content is the formal record of decisions made during a shareholder meeting, including voting results. This directly corresponds to the definition of materials shared during an Annual General Meeting (AGM) or Extraordinary General Meeting (EGM). Therefore, the appropriate classification is AGM-R (AGM Information).
2021-02-16 Polish
Uchwały podjęte przez Nadzwyczajne Walne Zgromadzenie Celon Pharma S.A. w dniu 16 lutego 2021 r. - Content (PL)
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document text is very short (464 characters) and explicitly states that the Management Board of Celon Pharma S.A. is enclosing the content of the resolutions ('treść uchwał') adopted by the Extraordinary General Meeting ('Nadzwyczajne Walne Zgromadzenie') held on February 16, 2021. This content is the result of a shareholder vote. The most specific category for official results from shareholder votes is 'Declaration of Voting Results & Voting Rights Announcements' (DVA). Although it contains the results, the context suggests it is the official announcement/filing of those results.
2021-02-16 Polish
Rezygnacja Członka Rady Nadzorczej Spółki - Content (PL)
Board/Management Information Classification · 1% confidence The document text is very short (337 characters) and announces the resignation of a member of the Supervisory Board (Rada Nadzorcza) effective upon the next General Shareholders' Meeting. This directly relates to changes in the company's board of directors or senior management. This aligns perfectly with the definition for Board/Management Information (MANG). It is not a full report, a dividend notice, or a general regulatory filing.
2021-02-11 Polish
Zarekomendowanie przez NCBR do dofinansowania projektu dotyczącego kandydata na lek inhalacyjny w terapii chorób płuc o podłożu zapalnym i fibrotycznym w tym powikłań COVID-19 - Content (PL)
Regulatory Filings Classification · 1% confidence The document is a formal announcement by the Management Board ('Zarząd') of Celon Pharma S.A. regarding the recommendation for funding ('dofinansowanie') of a specific R&D project by the National Centre for Research and Development ('NCBR'). This announcement details the project scope, costs (approx. 46.9 million PLN total, 27.2 million PLN recommended funding), and the intended use of the funds (clinical validation, toxicology studies for a new drug candidate CPL116). This type of communication, detailing fundraising, grants, or significant financing activities related to the company's operations and capital structure, aligns best with the 'Capital/Financing Update' category. It is not a standard regulatory report (10-K, IR), an earnings release (ER), or a management discussion (MDA), but rather a specific update on securing capital/funding for development.
2021-02-10 Polish
Zakończenie prowadzenia fazy IA badania klinicznego nad lekiem opartym o innowacyjny inhibitor JAK/ROCK – CPL 409116 - Content (PL)
Regulatory Filings Classification · 1% confidence The document text discusses the completion of Phase IA clinical trials for a drug candidate (CPL’116), detailing safety and pharmacokinetic results, and outlines plans for the next phase (IB). This content relates to ongoing research and development activities, specifically clinical trial updates. This type of specific operational/scientific update, especially concerning drug development phases, does not fit neatly into the standard financial reports (10-K, IR, ER) or corporate governance documents. It is a specific regulatory/operational announcement. Given the options, it is most closely related to a general regulatory announcement or a specific operational update. Since there is no specific 'Clinical Trial Update' code, and it is a formal announcement regarding a significant operational milestone (completion of a trial phase), it falls best under the general 'Regulatory Filings' (RNS) category as a miscellaneous, non-standard filing, or potentially a Legal/Regulatory update if the trial itself is regulatory-driven. Given the context of drug development milestones, RNS (Regulatory Filings) is the most appropriate fallback for specific operational news that isn't a standard financial report or management change.
2021-02-09 Polish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.